Waterloo Capital L.P. Trims Stake in Zoetis Inc. (NYSE:ZTS)

Waterloo Capital L.P. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 15.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,251 shares of the company’s stock after selling 233 shares during the quarter. Waterloo Capital L.P.’s holdings in Zoetis were worth $217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC lifted its position in Zoetis by 13.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 51,771 shares of the company’s stock valued at $8,899,000 after purchasing an additional 6,189 shares in the last quarter. Argent Trust Co lifted its position in shares of Zoetis by 10.2% during the 2nd quarter. Argent Trust Co now owns 22,902 shares of the company’s stock valued at $3,970,000 after buying an additional 2,125 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Zoetis by 12.3% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 49,298 shares of the company’s stock valued at $8,530,000 after acquiring an additional 5,384 shares during the period. Meiji Yasuda Life Insurance Co increased its holdings in Zoetis by 94.0% in the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 47,922 shares of the company’s stock worth $8,308,000 after acquiring an additional 23,225 shares in the last quarter. Finally, Wealth Alliance raised its stake in Zoetis by 6.2% during the 2nd quarter. Wealth Alliance now owns 12,759 shares of the company’s stock worth $2,212,000 after acquiring an additional 750 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.6 %

Shares of Zoetis stock opened at $193.24 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The business has a 50-day moving average price of $184.42 and a 200-day moving average price of $174.44. The firm has a market cap of $88.17 billion, a price-to-earnings ratio of 37.23, a PEG ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.41 EPS. Equities research analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.